IDEXX Laboratories, Inc. vs Peloton Interactive Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Peloton Interactive Inc trades at $5.11 (market cap $2.16B). The key difference: IDEXX Laboratories, Inc. is far larger — about 18.7× Peloton Interactive Inc's market cap, and Peloton Interactive Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Peloton Interactive Inc for 37 Days on average.
| IDXX | PTON | |
|---|---|---|
Market Cap | $40.43B | $2.16B |
Volume | 692,164 | 11,369,487 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $7.86 |
52-Week Low | $504.70 | $3.71 |
Typical Hold Time | 46 Days | 37 Days |
Enterprise Value | $41.32B | $2.66B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Peloton (PTON) trades at $5.06, up 4.33% on the day, but remains in a bearish technical trend. The company reported its first full-year net profit in fiscal 2026, with Q2 2026 EPS beating expectations at $0.13 versus $0.12, though revenue declined to $2.49B in 2025. Recent news highlights the launch of a new, more affordable Tread Flex treadmill and AI-powered coaching features as part of its turnaround strategy. Analyst consensus is a 'Buy' with a $8.00 price target, but negative shareholder equity and high debt levels pose significant risks.
The outlook is mixed; cost-cutting and new product launches support a path to sustained profitability, but subscriber declines, high leverage, and insider selling temper optimism. The stock offers speculative upside if execution improves, yet remains vulnerable to competitive pressures and macroeconomic headwinds. Investors should weigh the potential for operational turnaround against persistent financial and business model challenges.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →